vs
AVISTA CORP（AVA）与Royalty Pharma plc（RPRX）财务数据对比。点击上方公司名可切换其他公司
Royalty Pharma plc的季度营收约是AVISTA CORP的1.2倍（$622.0M vs $533.0M），Royalty Pharma plc净利率更高（34.4% vs 13.3%，领先21.1%），Royalty Pharma plc同比增速更快（4.8% vs 0.0%），过去两年Royalty Pharma plc的营收复合增速更高（4.6% vs -6.5%）
Avista Corporation是美国能源企业，业务涵盖发电、输电及天然气配送，服务覆盖住宅、商业与工业客户。公司拥有约1550名员工，为美国西部三个州的35.9万电力用户和32万天然气用户提供能源相关服务，业务区域覆盖华盛顿州东部、爱达荷州北部、俄勒冈州南部及东部部分区域，总面积达7.8万平方公里。
本公司是总部位于美国马萨诸塞州剑桥市的临床阶段生物制药企业，专注于研发可调节转化生长因子β（TGF-β）超家族蛋白的药物，该类蛋白在红细胞、肌肉、骨骼、血管等细胞与组织的生长修复过程中发挥核心作用。
AVA vs RPRX — 直观对比
营收规模更大
RPRX
是对方的1.2倍
$533.0M
营收增速更快
RPRX
高出4.7%
0.0%
净利率更高
RPRX
高出21.1%
13.3%
两年增速更快
RPRX
近两年复合增速
-6.5%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $533.0M | $622.0M |
| 净利润 | $71.0M | $214.2M |
| 毛利率 | — | — |
| 营业利润率 | 21.0% | 62.4% |
| 净利率 | 13.3% | 34.4% |
| 营收同比 | 0.0% | 4.8% |
| 净利润同比 | 5.7% | 2.9% |
| 每股收益（稀释后） | $0.87 | $0.49 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收AVARPRX
| Q4 25 | $533.0M | $622.0M | ||
| Q3 25 | $403.0M | $609.3M | ||
| Q2 25 | $411.0M | $578.7M | ||
| Q1 25 | $617.0M | $568.2M | ||
| Q4 24 | $532.8M | $593.6M | ||
| Q3 24 | $393.7M | $564.7M | ||
| Q2 24 | $402.1M | $537.3M | ||
| Q1 24 | $609.4M | $568.0M |
净利润AVARPRX
| Q4 25 | $71.0M | $214.2M | ||
| Q3 25 | $29.0M | $288.2M | ||
| Q2 25 | $14.0M | $30.2M | ||
| Q1 25 | $79.0M | $238.3M | ||
| Q4 24 | $67.2M | $208.2M | ||
| Q3 24 | $18.5M | $544.0M | ||
| Q2 24 | $22.9M | $102.0M | ||
| Q1 24 | $71.5M | $4.8M |
营业利润率AVARPRX
| Q4 25 | 21.0% | 62.4% | ||
| Q3 25 | 14.9% | 70.1% | ||
| Q2 25 | 13.9% | 36.3% | ||
| Q1 25 | 20.3% | 94.0% | ||
| Q4 24 | 19.1% | 60.9% | ||
| Q3 24 | 12.4% | — | ||
| Q2 24 | 13.5% | 50.2% | ||
| Q1 24 | 16.6% | -13.0% |
净利率AVARPRX
| Q4 25 | 13.3% | 34.4% | ||
| Q3 25 | 7.2% | 47.3% | ||
| Q2 25 | 3.4% | 5.2% | ||
| Q1 25 | 12.8% | 41.9% | ||
| Q4 24 | 12.6% | 35.1% | ||
| Q3 24 | 4.7% | 96.3% | ||
| Q2 24 | 5.7% | 19.0% | ||
| Q1 24 | 11.7% | 0.8% |
每股收益（稀释后）AVARPRX
| Q4 25 | $0.87 | $0.49 | ||
| Q3 25 | $0.36 | $0.67 | ||
| Q2 25 | $0.17 | $0.07 | ||
| Q1 25 | $0.98 | $0.55 | ||
| Q4 24 | $0.86 | $0.46 | ||
| Q3 24 | $0.23 | $1.21 | ||
| Q2 24 | $0.29 | $0.23 | ||
| Q1 24 | $0.91 | $0.01 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $19.0M | $618.7M |
| 总债务越低越好 | — | $9.0B |
| 股东权益账面价值 | $2.7B | $9.7B |
| 总资产 | $8.4B | $19.6B |
| 负债/权益比越低杠杆越低 | — | 0.92× |
8季度趋势，按日历期对齐
现金及短期投资AVARPRX
| Q4 25 | $19.0M | $618.7M | ||
| Q3 25 | $44.0M | $938.9M | ||
| Q2 25 | $9.0M | $631.9M | ||
| Q1 25 | $17.0M | $1.1B | ||
| Q4 24 | $30.0M | $929.0M | ||
| Q3 24 | $9.1M | $950.1M | ||
| Q2 24 | $14.6M | $1.8B | ||
| Q1 24 | $12.3M | $843.0M |
总债务AVARPRX
| Q4 25 | — | $9.0B | ||
| Q3 25 | — | $8.9B | ||
| Q2 25 | — | $8.0B | ||
| Q1 25 | — | $7.6B | ||
| Q4 24 | — | $7.6B | ||
| Q3 24 | — | $7.6B | ||
| Q2 24 | — | $7.6B | ||
| Q1 24 | — | $6.1B |
股东权益AVARPRX
| Q4 25 | $2.7B | $9.7B | ||
| Q3 25 | $2.6B | $9.6B | ||
| Q2 25 | $2.6B | $9.5B | ||
| Q1 25 | $2.6B | $9.8B | ||
| Q4 24 | $2.6B | $10.3B | ||
| Q3 24 | $2.5B | $10.3B | ||
| Q2 24 | $2.5B | $9.8B | ||
| Q1 24 | $2.5B | $9.9B |
总资产AVARPRX
| Q4 25 | $8.4B | $19.6B | ||
| Q3 25 | $8.2B | $19.3B | ||
| Q2 25 | $8.1B | $18.3B | ||
| Q1 25 | $8.0B | $17.6B | ||
| Q4 24 | $7.9B | $18.2B | ||
| Q3 24 | $7.8B | $18.0B | ||
| Q2 24 | $7.7B | $17.7B | ||
| Q1 24 | $7.6B | $16.1B |
负债/权益比AVARPRX
| Q4 25 | — | 0.92× | ||
| Q3 25 | — | 0.93× | ||
| Q2 25 | — | 0.84× | ||
| Q1 25 | — | 0.78× | ||
| Q4 24 | — | 0.74× | ||
| Q3 24 | — | 0.74× | ||
| Q2 24 | — | 0.78× | ||
| Q1 24 | — | 0.62× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $75.0M | $827.1M |
| 自由现金流经营现金流 - 资本支出 | $-116.0M | — |
| 自由现金流率自由现金流/营收 | -21.8% | — |
| 资本支出强度资本支出/营收 | 35.8% | — |
| 现金转化率经营现金流/净利润 | 1.06× | 3.86× |
| 过去12个月自由现金流最近4个季度 | $-101.0M | — |
8季度趋势，按日历期对齐
经营现金流AVARPRX
| Q4 25 | $75.0M | $827.1M | ||
| Q3 25 | $170.0M | $702.6M | ||
| Q2 25 | $40.0M | $364.0M | ||
| Q1 25 | $184.0M | $596.1M | ||
| Q4 24 | $89.8M | $742.5M | ||
| Q3 24 | $127.2M | $703.6M | ||
| Q2 24 | $126.8M | $658.2M | ||
| Q1 24 | $190.1M | $664.6M |
自由现金流AVARPRX
| Q4 25 | $-116.0M | — | ||
| Q3 25 | $37.0M | — | ||
| Q2 25 | $-103.0M | — | ||
| Q1 25 | $81.0M | — | ||
| Q4 24 | $-37.8M | — | ||
| Q3 24 | $-27.0M | — | ||
| Q2 24 | $-5.7M | — | ||
| Q1 24 | $71.4M | — |
自由现金流率AVARPRX
| Q4 25 | -21.8% | — | ||
| Q3 25 | 9.2% | — | ||
| Q2 25 | -25.1% | — | ||
| Q1 25 | 13.1% | — | ||
| Q4 24 | -7.1% | — | ||
| Q3 24 | -6.9% | — | ||
| Q2 24 | -1.4% | — | ||
| Q1 24 | 11.7% | — |
资本支出强度AVARPRX
| Q4 25 | 35.8% | — | ||
| Q3 25 | 33.0% | — | ||
| Q2 25 | 34.8% | — | ||
| Q1 25 | 16.7% | — | ||
| Q4 24 | 23.9% | — | ||
| Q3 24 | 39.2% | — | ||
| Q2 24 | 33.0% | — | ||
| Q1 24 | 19.5% | — |
现金转化率AVARPRX
| Q4 25 | 1.06× | 3.86× | ||
| Q3 25 | 5.86× | 2.44× | ||
| Q2 25 | 2.86× | 12.06× | ||
| Q1 25 | 2.33× | 2.50× | ||
| Q4 24 | 1.34× | 3.57× | ||
| Q3 24 | 6.88× | 1.29× | ||
| Q2 24 | 5.55× | 6.45× | ||
| Q1 24 | 2.66× | 139.10× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
AVA
暂无分部数据
RPRX
| Financial Royalty Assets | $592.4M | 95% |
| Royalty Income Other | $29.6M | 5% |
